National Academies Press: OpenBook
« Previous: Appendix B: Workshop Agenda
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

C

Registered Attendees

Neeraj Agarwal

National Eye Institute

Brittany Aguilar

Georgetown University

Cara Altimus

Food and Drug Administration

Sam Alworth

AcuraStem, Inc.

Susan Amara

National Institute of Mental Health

Kim Andersen

H. Lundbeck A/S

Megan Anderson Brooks

Cavarocchi Ruscio Dennis Associates, LLC

Irina Antonijevic

Sanofi Genzyme

Alexander Arguello

Nature Neuroscience

Aisar Atrakchi

Food and Drug Administration

Shelli Avenevoli

National Institute of Mental Health

Rita Balice-Gordon

Sanofi

Grant Belgard

Verge Genomics

Lizbet Boroughs

Association of American Universities

Linda Brady

National Institute of Mental Health

Katja Brose

Neuron, Cell Press

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

Lucie Bruijn

The ALS Association

Gregory Busse

Takeda Pharmaceuticals U.S.A., Inc.

Sarah Caddick

The Gatsby Charitable Foundation

Rosa Canet-Aviles

Foundation for the National Institutes of Health

Franklin Carrero-Martinez

National Science Foundation

Elzbieta Chalecka-Franaszek

Food and Drug Administration

Karen Chandross

Sanofi

Jason Chen

Verge Genomics

Tess Chidlow

Private Practice

Jonathan Cohen

Princeton University

Doug Cole

Flagship Ventures

Robert Conley

Eli Lilly and Company

Charles Cywin

National Institute of Neurological Disorders and Stroke

James Deshler

National Science Foundation

Dario Doller

Concert Pharmaceuticals, Inc.

Rebecca Dresser

Washington University Law School

Billy Dunn

Food and Drug Administration

Emmeline Edwards

National Center for Complementary and Integrative Health

Jan Egebjerg

H. Lundbeck A/S

Nita Farahany

Duke University School of Law

Mehdi Farokhnia

National Institutes of Health

Guoping Feng

Massachusetts Institute of Technology

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

Steve Finkbeiner

Gladstone Institute of Neurological Disease, University of California, San Francisco

Stephen Fischer

Walter Reed National Military Medical Center

Allyson Gage

Cohen Veterans Bioscience

Marjorie Garvey

National Institute of Mental Health

Hugo Geerts

In Silico Biosciences, Inc.

Chris Gorini

Food and Drug Administration

Meg Grabb

National Institute of Mental Health

Henry Greely

Stanford University

Magali Haas

Cohen Veterans Bioscience

Jeri Hallberg Harmon Griffin Tamez

Vantage College

Dean Hartley

Alzheimer’s Association

Deborah Hartman

Takeda Pharmaceuticals U.S.A., Inc.

Thomas Hartung

Johns Hopkins Bloomberg School of Public Health

Ramona Hicks

One Mind

Richard Hodes

National Institutes of Health

Stuart Hoffman

Department of Veterans Affairs

Stephen Huhn

StemCells, Inc.

Steven Hyman

Stanley Center for Psychiatric Research

Debbie Indyk

Icahn School of Medicine at Mount Sinai

Tom Jacobs

The University of Texas System

Frances Jensen

Perelman School of Medicine at the University of Pennsylvania

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

Sophia Jeon

National Institute of Neurological Disorders and Stroke

Nina Jochnowitz

Merck & Co., Inc.

John Kehne

National Institute of Neurological Disorders and Stroke

Melinda Kelley

National Institute on Aging

Sooja Kim

American Institute for Cancer Research

George Koob

National Institute on Alcohol Abuse and Alcoholism

Walter Koroshetz

National Institute of Neurological Disorders and Stroke

Victor Krauthamer

Food and Drug Administration

John Krystal

Yale School of Medicine

Pascal Laeng

National Institute of Neurological Disorders and Stroke

Story Landis

National Institute of Neurological Disorders and Stroke, Emeritus

Jane Larkindale

Critical Path Institute

Judith Lelchook

The Solace Center

Alan Leshner

American Association for the Advancement of Science, Emeritus

Feng-Yen Li

Physicians Committee for Responsible Medicine

Roger Little

National Institute on Drug Abuse

Glenn Mannheim

Food and Drug Administration

Bill Martin

BlackThorn Therapeutics, Inc.

David Michelson

Merck & Co., Inc.

Meghan Mott

National Institute of Neurological Disorders and Stroke

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

Amy Muhlberg

Parkinson Wellness Recovery

Jonathan Nassi

Inscopix, Inc.

Jorge L. Nina Espinosa

University of Puerto Rico, Medical Sciences Campus

James Olds

National Science Foundation

Alex Ommaya

Association of American Medical Colleges

Mary Pelleymounter

National Institute of Neurological Disorders and Stroke

Niels Plath

H. Lundbeck A/S

Sridevi Polavaram

George Mason University

Linda Porter

National Institute of Neurological Disorders and Stroke

William Potter

National Institute of Mental Health

Shamsi Raeissi

National Institute of Neurological Disorders and Stroke

Tanya Ramey

National Institute on Drug Abuse

Arippa Ravindran

Food and Drug Administration

John Reppas

Neurotechnology Industry Organization

Lee Rubin

Harvard University

Alexander Runko

Office of Research Integrity, Department of Health and Human Services

Erik Runko

National Science Foundation

John Michael Sauer

Critical Path Institute

Irina Sazonova

National Institute on Drug Abuse

Eugenia Schenecker

George Washington University

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×

Todd Sherer

The Michael J. Fox Foundation for Parkinson’s Research

Sara Shnider

Prize4Life, Inc.

David Shurtleff

National Center for Complementary and Integrative Health

Paul Sieving

National Eye Institute

Kurt Spindler

Neurocurious

Michael Steinmetz

National Eye Institute

Robert Temple

Food and Drug Administration

William Thies

Alzheimer’s Association

Wendy Toler

Consultant

Jon VanLeeuwen

University of California, San Francisco

Meredith Wadman

Science Magazine

Hao Wang

National Institute of Neurological Disorders and Stroke

Alan Willard

National Institute of Neurological Disorders and Stroke

Doug Williamson

Lundbeck

Ling Wong

National Institute of Neurological Disorders and Stroke

Winifred Wu

Strategic Regulatory Partners, LLC

Suzanne Yang

Uniformed Services University of the Health Sciences

Robert Zalutsky

National Institute of Neurological Disorders and Stroke

Alice Zhang

Jason Zhang

WAVE Life Sciences, Ltd.

Stevin Zorn

MindImmune Therapeutics, Inc.

Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 77
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 78
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 79
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 80
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 81
Suggested Citation:"Appendix C: Registered Attendees." National Academies of Sciences, Engineering, and Medicine. 2017. Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/24672.
×
Page 82
Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop Get This Book
×
 Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders: Proceedings of a Workshop
Buy Paperback | $55.00 Buy Ebook | $44.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders.

In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!